★
PSNL
Personalis Inc · Life Sciences Tools & Services
FCF-$85mF
Rev-20.7%F
D/E0.12A-
P/S18.5xC
PEG——
52Score
$11.411Y Target$15.40Near-term target
5Y Target$22.95Compound horizon
10Y Target$59.72Long-dated conviction
FCF-$85mTTM · 03/26F
FCF is negative (-$85m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev-20.7%TTM YoYF
Revenue -20.7% — severe decline · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.12totalA-
D/E 0.12 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S18.5xC
P/S 18.5x — elevated; requires growth to justify
PEG—proxy—
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Life Sciences Tools & Services · market cap $1.2b. 4% off the 52-week high of $11.85. Revenue -21% — in contraction; any catalyst that reverses this triggers re-rating.
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Free cash flow is negative (-$85m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -21% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -148.1%) — path to GAAP profitability is the core thesis risk.
Horizon
1-3 yr $15.40 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $22.95 — requires the platform / technology to reach commercial scale. 10 yr $59.72 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · PSNL
Shares to buy
175
Position size
$1,997
4.0% of portfolio
Stop price
$8.56
25% below $11.41
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.